Key Takeaways Tempus AI's Genomics revenues jumped 115% year over year, driven by testing growth and acquisitions. Exact Sciences' genomics advances include Oncotype DX and Oncodetect validation in colorectal cancer. EXAS offers a stronger earnings outlook and valuation appeal, while TEM leads in share performance. Per multiple sources, the integration of genomics into cancer care has transformed treatment approaches, moving away from uniform therapies to precision medicine, where clinical decisions are tai ...

Core Insights - Quest Diagnostics (DGX) has partnered with Haystack Oncology and Rutgers Cancer Institute to evaluate the Haystack MRD test for optimizing postoperative therapy in stage II/III non-small cell lung cancer (NSCLC) patients [1][3][9] Company Developments - Haystack MRD is a lab-developed test (LDT) validated in a CLIA-certified laboratory and is commercially available through Quest Diagnostics [2][9] - The MRD-PORT Trial (NCT06979661) is a prospective phase II study assessing the use of Haystack MRD to guide postoperative radiation and systemic therapies based on residual tumor DNA presence [3][4] - In addition to the lung cancer study, a previous collaboration in 2023 focused on using Haystack MRD for early-stage triple-negative breast cancer treatment [3] Industry Prospects - The global minimal residual disease (MRD) market was valued at $2.50 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 10.1% through 2030, driven by rising cancer incidence, technological advancements, and integration with personalized medicine [6] - The FDA granted Breakthrough Device Designation to Haystack MRD for identifying MRD-positive patients with stage II colorectal cancer, indicating its potential in guiding adjuvant therapy [5] Other Developments in the Industry - Quest Diagnostics has introduced an advanced pharmacogenomic (PGx) laboratory test service to help providers understand patients' genetic responses to drug therapies, aiming to prevent therapeutic failures and adverse drug interactions [7] - Competitors like QIAGEN and Exact Sciences are also advancing in the molecular diagnostics space, with QIAGEN achieving CE-IVDR certification for its testing systems and Exact Sciences launching a multi-cancer early detection blood test [8][11]

Company Overview - Exact Sciences Corporation (EXAS) has launched the Cancerguard test, a multi-cancer early detection (MCED) blood test, which is the first commercially available test of its kind in the U.S. [1] - The Cancerguard test is designed for individuals aged 50-84 with no known cancer diagnosis in the past three years and can be considered annually [2] Product Details - The Cancerguard test analyzes multiple biomarker classes to detect a wide range of cancers, including those that often go undiagnosed until later stages [1] - The test can detect signals from over 50 cancer types and subtypes, including high-mortality cancers such as pancreatic, ovarian, liver, esophageal, lung, and stomach cancers [5] - It has shown 68% sensitivity across six of the deadliest cancers and 64% overall sensitivity across a broader range of cancers, excluding breast and prostate [6] - The test achieves a specificity of 97.4%, minimizing false positives and avoiding unnecessary procedures [6] Market Performance - Following the announcement of the Cancerguard test, EXAS shares rose 2.2%, closing at $56.0 [3] - Exact Sciences has a current market capitalization of $10.37 billion [4] - In the past six months, EXAS shares have increased by 29.8%, while the industry has seen a decline of 1.2% [13] Future Prospects - The global MCED market is projected to be worth $1.12 billion in 2025, with a compound annual growth rate of 17% through 2030, driven by the rising prevalence of multiple cancers [11] - The company is actively enrolling up to 25,000 participants in the Falcon Registry Real-World Evidence study to support future regulatory submissions and payer discussions [7][9] Recent Developments - Exact Sciences has acquired exclusive U.S. rights to current and future versions of Freenome's blood-based colorectal cancer screening tests [12] - The company has partnered with Quest Diagnostics to enable blood collection at approximately 7,000 patient access sites across the U.S. [10]

Group 1: TransMedics Group - TransMedics Group has developed an innovative Organ Care System (OCS) that significantly improves organ storage before transplants, achieving an 81% usage rate for hearts compared to 32% for traditional cold storage [4] - The company has faced challenges, including slowed revenue growth and disappointing guidance, alongside serious allegations from an activist short-seller [5] - Despite recent issues, TransMedics Group's stock rose approximately 20% following stronger-than-expected first-quarter results, although shares are still down 11% over the past year, indicating potential for significant upside in the next five years [6][7] Group 2: Exact Sciences - Exact Sciences specializes in cancer diagnostic tests, notably Cologuard, a non-invasive test for colorectal cancer, which is the second leading cause of cancer death globally [8] - The company has made substantial progress in the screening market, with Cologuard being used to screen 10 million patients by 2022 since its U.S. clearance in 2014 [9] - Recent advancements include the approval of Cologuard Plus, which is more effective and cheaper to manufacture, and the launch of Oncodetect for cancer recurrence checks, with plans for a multicancer-detecting test called Cancerguard later this year [10][11][12]